Last update 08 May 2025

KRAS G12D x RNF152

Basic Info

Related Targets
KRAS G12DRNF152

Related

1
Drugs associated with KRAS G12D x RNF152
KRAS G12D LYMTAC (Amgen)
Target
KRAS G12D x RNF152
Mechanism
KRAS G12D inhibitors [+1]
Active Org.
Amgen, Inc.Amgen, Inc.
Originator Org.
Amgen, Inc.Amgen, Inc.
Active Indication
Neoplasms
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
100 Clinical Results associated with KRAS G12D x RNF152
Login to view more data
100 Translational Medicine associated with KRAS G12D x RNF152
Login to view more data
0 Patents (Medical) associated with KRAS G12D x RNF152
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free